AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

December 23, 2020 GMT

LOS ANGELES--(BUSINESS WIRE)--Dec 23, 2020--

The Law Offices of Frank R. Cruz announces an investigation of Genfit S.A. (“Genfit” or the “Company”) (NASDAQ: GNFT ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

ADVERTISEMENT

If you are a shareholder who suffered a loss, click here to participate.

Genfit is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology.

In March 2019, the Company completed its initial public offering (“IPO”), in which it sold 6,150,000 ordinary shares in the form of American Depositary Shares (“ADSs” or “shares”) in the U.S. and Europe for $20.32 per ADS.

On February 20, 2020, after the market closed, Genfit announced in a press release a delay in the release of topline interim results from the RESOLVE-IT study. The Company stated, among other things, that the delay was “to incorporate the latest FDA insights expected by the end of March” and that “[t]his decision has been taken to ensure that the latest thinking in the NASH field is properly captured so the Company can optimize elafibranor’s NDA dossier at the time of submission.”

On this news, Genfit’s share price fell $1.05, or nearly 6%, over two consecutive trading sessions to close at $16.85 per share on February 24, 2020, thereby injuring investors.

On May 11, 2020, after the market closed, Genfit announced results from an interim analysis of the RESOLVE-IT Phase 3 study of elafibranor, including that “[e]lafibranor did not demonstrate a statistically significant effect on the primary endpoint of NASH resolution without worsening of fibrosis.”

ADVERTISEMENT

On this news, Genfit’s share price fell $14.90, or approximately 68%, to close at $7.10 per share on May 12, 2020, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Genfit securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com:https://www.businesswire.com/news/home/20201223005065/en/

CONTACT: The Law Offices of Frank R. Cruz, Los Angeles

Frank R. Cruz, 310-914-5007

fcruz@frankcruzlaw.com

www.frankcruzlaw.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: LEGAL PROFESSIONAL SERVICES

SOURCE: The Law Offices of Frank R. Cruz

Copyright Business Wire 2020.

PUB: 12/23/2020 02:00 PM/DISC: 12/23/2020 02:00 PM

http://www.businesswire.com/news/home/20201223005065/en